News

Sprint Bioscience attends BioPartnering North America 2012 in Vancouver, Canada, 26-28 February.

Sprint Bioscience Medicinal Chemistry team is pleased to announce that Dr. Fredrik Rahm will join us from AstraZeneca in the position as Principal Scientist starting December 1. Fredrik will strengthen Sprint Bioscience by bringing several years of fragment based drug … Continue reading →

Sprint Bioscience is featured in the article in Science Business eXchange on autophagy inhibition in cancer treatment. SciBX 4(42); doi:10.1038/scibx.2011.1166 Published online Oct. 27 2011 Taking down autophagy – Nature

partneringNEWS™ published an article about Sprint Bioscience and fragment-based drug discovery. Sprint Bioscience: Kick start for drug discovery with fragment-based screening

Sprint Bioscience, a fragment based drug discovery company, is growing its CRO business and speeds up the development of their in-house cancer metabolism pipe line. In alliance with the company expansion, we are happy to welcome three new colleagues; Anne-Marie … Continue reading →

Sprint Bioscience attends Partnering at BIO-Europe® 2011  in Dusseldorf, Germany, October 31 – November 2.

New review article in Current Opinion in Chemical Biology co-authored by Sprint Bioscience CEO, Dr. Anders Åberg http://www.sciencedirect.com/science/article/pii/S1367593111001013

“Autophagy, the process of “self-eating” within cells, has been controversial in cancer since it was first linked to the disease in 1999. Because autophagy can either suppress or promote tumors, depending on the context. A consensus is emerging that it’s the … Continue reading →